How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Relapsed Acute Myeloid Leukemia Drug Market
- By Drug Class: Hypomethylating Agents (HMAs), BCL-2 Inhibitors, FLT3 Inhibitors, IDH1/IDH2 Inhibitors, Chemotherapy Agents
- By Mechanism of Action: DNA Methyltransferase Inhibition, Apoptosis Induction, Tyrosine Kinase Inhibition, Metabolic Enzyme Inhibition, Cytotoxic Chemotherapy
- By Line of Therapy: Second-line Treatment, Third-line Treatment, Salvage Therapy, Bridge to Transplant Therapy
- By Patient Population: Elderly Patients, Younger Adult Patients, Patients with FLT3 Mutation, Patients with IDH1/IDH2 Mutation, Patients with Secondary AML
- By Formulation: Oral Formulations, Intravenous Formulations, Subcutaneous Formulations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hypomethylating Agents (HMAs) leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Relapsed Acute Myeloid Leukemia Drug Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Mechanism of Action 5
Line of Therapy 4
Patient Population 5
Formulation 3
Companies profiled
Novartis AG
Pfizer Inc.
Jazz Pharmaceuticals plc
Astellas Pharma Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Agios Pharmaceuticals Inc.
Daiichi Sankyo Company
Limited
Takeda Pharmaceutical Company Limited
Amgen Inc.
Gilead Sciences Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Jazz Pharmaceuticals plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Astellas Pharma Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Agios Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Daiichi Sankyo Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Takeda Pharmaceutical Company Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Gilead Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Celgene Corporation (a Bristol-Myers Squibb company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sunesis Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Onconova Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Kite Pharma (a Gilead company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,580M by 2033 · 8.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hypomethylating Agents (HMAs)53.2
- BCL-2 Inhibitors11.5
- FLT3 Inhibitors12.1
- IDH1/IDH2 Inhibitors11.3
- Chemotherapy Agents11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,111M → $2,243M · 9.2%
Europe$774.0M → $1,425M · 7.9%
Asia Pacific$706.7M → $1,484M · 9.7%
Latin America$437.5M → $950.0M · 10.2%
Middle East and Africa$336.5M → $615.5M · 7.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.702026
8.712027
8.722028
8.722029
8.742030
8.752031
8.772032
8.782033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG12.9
- Pfizer Inc.13.9
- Jazz Pharmaceuticals plc11.0
- Astellas Pharma Inc.9.9
- AbbVie Inc.12.0
- Bristol-Myers Squibb Company12.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class18.9%
Mechanism of Action16.1%
Line of Therapy18.3%
Patient Population24.3%
Formulation22.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.4
- Europe21.2
- Asia Pacific22.1
- Latin America14.1
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 88 | 95 | 84 | 89 | 85 | 94 | 89 |
| Pfizer Inc. | 72 | 74 | 89 | 77 | 73 | 73 | 76 |
| Jazz Pharmaceuticals plc | 74 | 72 | 79 | 70 | 72 | 70 | 73 |
| Astellas Pharma Inc. | 65 | 74 | 73 | 58 | 73 | 64 | 68 |
| AbbVie Inc. | 76 | 52 | 59 | 62 | 72 | 54 | 63 |
| Bristol-Myers Squibb Company | 46 | 58 | 62 | 71 | 46 | 53 | 56 |
| Agios Pharmaceuticals Inc. | 58 | 64 | 65 | 56 | 65 | 42 | 58 |
| Daiichi Sankyo Company | 52 | 53 | 60 | 42 | 45 | 52 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Pfizer Inc.
- Jazz Pharmaceuticals plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Pfizer Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Jazz Pharmaceuticals plc | ✓ | ◐ | ◐ | − | ◐ | ✓ |
| Astellas Pharma Inc. | ◐ | ✓ | ✓ | − | ◐ | ◐ |
| AbbVie Inc. | ✓ | ◐ | − | − | ✓ | − |
| Bristol-Myers Squibb Company | − | ◐ | ◐ | ✓ | − | − |
| Agios Pharmaceuticals Inc. | − | − | ◐ | ◐ | − | − |
| Daiichi Sankyo Company | − | ◐ | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG89
2Pfizer Inc.76
3Jazz Pharmaceuticals plc73
4Astellas Pharma Inc.68
5AbbVie Inc.63
6Agios Pharmaceuticals Inc.58
7Bristol-Myers Squibb Company56
8Daiichi Sankyo Company51
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Novartis AG
Challenger3
Strong scale, closing on the leaders.
Pfizer Inc.Jazz Pharmaceuticals plcAstellas Pharma Inc.
Contender2
Focused players with pockets of strength.
AbbVie Inc.Agios Pharmaceuticals Inc.
Niche2
Specialists in a single segment or region.
Bristol-Myers Squibb CompanyDaiichi Sankyo Company
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Relapsed Acute Myeloid Leukemia Drug Market — a $589M beachhead inside a $11.1B market.
Beachhead (SOM)$589Mobtainable near-term
Serviceable (SAM)$4.20Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Hypomethylating Agents (HMAs)
Best fit — highest urgency & budget in Drug Class.
Economic buyer80 fit
BCL-2 Inhibitors
Strong fit — clear ROI and a fast path to value.
End user68 fit
FLT3 Inhibitors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Mechanism of Action & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Line of Therapy
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Relapsed Acute Myeloid Leukemia Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified22%
Evaluation12%
Closed-won7%
$10.9KCAC
$50KLTV
4.6:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Relapsed Acute Myeloid Leukemia Drug Market is a durable-growth opportunity — $10.1B by 2033, compounding at 9.3%.
TAM · 2025$4.95Btoday
TAM · 2033$10.1Bforecast
CAGR9.3%2027–2033
Cumulative$65.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.1BTotal addressable market
SAM$3.76BServiceable available market
SOM$660MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.1BLarge & growingTAM by 2033 at 9.3% CAGR
$3.76BServiceable nowreachable with today’s model
$660MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.88BBear6.1% CAGR
$10.1BBase9.3% CAGR
$12.9BBull12.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Mechanism of Action optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Relapsed Acute Myeloid Leukemia Drug Market — a $8.51B market by 2033. Plan: grow share from 6.9% to 11.2%.
Market size · 2033$8.51Btotal addressable
Market CAGR9.2%2027–2033
Target share11.2%from 6.9% today
Revenue ambition$953Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 11.2% | On track |
| Revenue | $626M | $953M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 35.9% | 45.3% | Ahead |
| Customer retention | 86.6% | 94.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Mechanism of Action capability
A defensible second engine — invest in Mechanism of Action to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Mechanism of Action
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $117M capacity & capability investment
- Greenlight bolt-on M&A in Mechanism of Action
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Relapsed Acute Myeloid Leukemia Drug Market conversation — a $3.15B market you can size, segment and defend in minutes.
Market size · 2033$3.15Btotal opportunity
Growth6.5%CAGR to 2033
Addressable buyers1,689+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 2 mopayback period
$66K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Novartis AGPfizer Inc.Jazz Pharmaceuticals plcAstellas Pharma Inc.AbbVie Inc.Bristol-Myers Squibb CompanyAgios Pharmaceuticals Inc.Daiichi Sankyo Company+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Relapsed Acute Myeloid Leukemia Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Relapsed Acute Myeloid Leukemia Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Reishi Mushroom Supplements Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportTherapeutic Radiopharmaceuticals Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportTherapeutic Radioisotopes Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportTherapeutic Proteins for Cardiovascular Disorders Treatment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe Contract Research (CRO) Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportTamsulosin Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportTadalafil Oral Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportSuperoxide Dismutase [Cu-Zn] Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportPost-Polycythemia Vera Myelofibrosis (PPV-MF) Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportPolymerase Chain Reaction (PCR) Test Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportSophocarpidine (CAS:519-02-8) Market
Market size, share, segmentation and regional forecast.
$643M market · 2025 base year
View reportSomatostatin Receptor Type 4 Market
Market size, share, segmentation and regional forecast.
$489M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.